Modeled Nucresiran Efficacy -- 95% median TTR knockdown with modeled expectations that 99% of patients will surpass the deep knockdown threshold. Management expressed continued confidence in the Phase III TRITON-CM trial for nucresiran, emphasizing modeled TTR knockdown data that exceeds competitor profiles. As we reflect on the launch, several insights reinforce our confidence in the durability of AMVUTTRA growth over the years ahead. Second, nucresiran's depth of TTR knockdown is expected to be best-in-class based on preliminary Phase I results showing over 95% TTR knockdown with much tighter intra-patient variability. Here, we show TTR knockdown from our polyneuropathy studies, which have the richest sampling of TTR levels.